<DOC>
	<DOCNO>NCT01607125</DOCNO>
	<brief_summary>The purpose study determine Vortioxetine 20 mg/day lead change neural activity ( BOLD signal ) , measure use fMRI , brain area associate executive function memory cognitive task performance compare placebo subject remit depression control , explore Vortioxetine lead improve cognitive performance absence depression .</brief_summary>
	<brief_title>Exploratory Study Effects Vortioxetine ( Lu AA21004 ) Cognition Blood Oxygen Level Dependent ( BOLD ) Functional Magnetic Resonance Imaging ( fMRI ) Signals Subjects Remitted From Depression Controls</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>All subject must : Hamilton Depression Rating Scale ( HAMD17 ) total score â‰¤ 7 Subjects remit depression must : remission recurrent depression suffer least two previous Major Depressive Episodes ( MDEs ) receive prescribed treatment antidepressant recognise psychotherapy depression previous MDE report present subjective cognitive dysfunction treat antidepressant receive psychotherapy depression least six week prior screen visit Control group subject must : history MDEs history MDEs biological parent first degree relative report subject report present subjective cognitive dysfunction never treat antidepressant psychotherapy The subject , opinion investigator , unlikely comply clinical study protocol unsuitable reason Other inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>